A D1 Receptor Antagonist, Ecopipam, for Treatment of Tics in Tourette Syndrome

Abstract

In this open-label study in adults with TS, tics were reduced after 8 weeks of treatment with ecopipam. To confirm safety and efficacy, randomized, double blind, placebo-controlled trials are warranted.